Tenon Medical (NASDAQ:TNON) vs. TriSalus Life Sciences (NASDAQ:TLSI) Head to Head Survey

TriSalus Life Sciences (NASDAQ:TLSI) and Tenon Medical (NASDAQ:TNON) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, earnings and institutional ownership.

Profitability

This table compares TriSalus Life Sciences and Tenon Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TriSalus Life Sciences	-206.24%	N/A	-236.83%
Tenon Medical	-413.88%	-1,785.88%	-164.26%

Risk and Volatility

TriSalus Life Sciences has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500. Comparatively, Tenon Medical has a beta of 1.89, indicating that its stock price is 89% more volatile than the S&P 500.

Institutional & Insider Ownership

2.6% of TriSalus Life Sciences shares are owned by institutional investors. Comparatively, 22.7% of Tenon Medical shares are owned by institutional investors. 32.8% of TriSalus Life Sciences shares are owned by insiders. Comparatively, 4.7% of Tenon Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares TriSalus Life Sciences and Tenon Medical”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TriSalus Life Sciences	$18.51 million	8.86	-$59.04 million	($2.49)	-2.16
Tenon Medical	$2.93 million	1.65	-$15.58 million	($27.23)	-0.06

Tenon Medical has lower revenue, but higher earnings than TriSalus Life Sciences. TriSalus Life Sciences is trading at a lower price-to-earnings ratio than Tenon Medical, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for TriSalus Life Sciences and Tenon Medical, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TriSalus Life Sciences	0	0	7	2	3.22
Tenon Medical	0	0	2	0	3.00

TriSalus Life Sciences presently has a consensus target price of $11.79, suggesting a potential upside of 119.07%. Tenon Medical has a consensus target price of $5.50, suggesting a potential upside of 257.14%. Given Tenon Medical’s higher probable upside, analysts clearly believe Tenon Medical is more favorable than TriSalus Life Sciences.

Summary

TriSalus Life Sciences beats Tenon Medical on 9 of the 15 factors compared between the two stocks.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.

About Tenon Medical

Tenon Medical, Inc., a medical device company, engages in the development of surgical implant systems to treat severe lower back pain in the United States and Puerto Rico. The company offers CATAMARAN SI-Joint Fusion System to fuse sacroiliac joints (SI-Joints) to treat SI-Joint dysfunction that often causes severe lower back pain; and features fixation device that passes through the axial and sagittal planes of the ilium and sacrum, as well as transfixes the SI joints. Tenon Medical, Inc. was incorporated in 2012 and is headquartered in Los Gatos, California.